Abstract
Drug delivery systems are designed to improve therapy efficacy as well as patient compliance. This could be accomplished by specifically targeting a medication intact to its active site, therefore reducing side-effects and enabling high local drug concentrations. Silica nanoparticles have gained ground in the biomedical field for their biocompatibility and biodegradability, being themselves inert and stable, thus enabling a variety of formulation designs for application in the pharmaceutical industry. This paper is a review of the recent patents on the applications of silica nanoparticles for drug delivery and their preparation. The review will focus on the different techniques available to obtain silica nanoparticles with variable morphology and their drug targeting applications, providing an overview of silica particles synthesis described in the literature.
Keywords: Drug delivery, controlled release, hollow silica nanoparticles, nanoparticles, silica, silica aerogels, targeted delivery, synthetic polymer, lower toxic effects, fabricate, biodegradability, polymorphonuclear leukocytes, porosity change, HSNP, TEOS
Recent Patents on Biotechnology
Title: Recent Patents on the Synthesis and Application of Silica Nanoparticles for Drug Delivery
Volume: 5 Issue: 1
Author(s): Maria Lucia Foglia, Gisela Solange Alvarez, Paolo Nicolas Catalano, Andrea Mathilde Mebert, Luis Eduardo Diaz, Thibaud Coradin and Martin Federico Desimone
Affiliation:
Keywords: Drug delivery, controlled release, hollow silica nanoparticles, nanoparticles, silica, silica aerogels, targeted delivery, synthetic polymer, lower toxic effects, fabricate, biodegradability, polymorphonuclear leukocytes, porosity change, HSNP, TEOS
Abstract: Drug delivery systems are designed to improve therapy efficacy as well as patient compliance. This could be accomplished by specifically targeting a medication intact to its active site, therefore reducing side-effects and enabling high local drug concentrations. Silica nanoparticles have gained ground in the biomedical field for their biocompatibility and biodegradability, being themselves inert and stable, thus enabling a variety of formulation designs for application in the pharmaceutical industry. This paper is a review of the recent patents on the applications of silica nanoparticles for drug delivery and their preparation. The review will focus on the different techniques available to obtain silica nanoparticles with variable morphology and their drug targeting applications, providing an overview of silica particles synthesis described in the literature.
Export Options
About this article
Cite this article as:
Lucia Foglia Maria, Solange Alvarez Gisela, Nicolas Catalano Paolo, Mathilde Mebert Andrea, Eduardo Diaz Luis, Coradin Thibaud and Federico Desimone Martin, Recent Patents on the Synthesis and Application of Silica Nanoparticles for Drug Delivery, Recent Patents on Biotechnology 2011; 5 (1) . https://dx.doi.org/10.2174/187220811795655887
DOI https://dx.doi.org/10.2174/187220811795655887 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients
Current Drug Targets Molecular Targeted Therapy of Gastrointestinal Stromal Tumors
Current Cancer Drug Targets Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism Overexpression of <i>microRNA-21</i> in the Serum of Breast Cancer Patients
MicroRNA Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Effective and Promising Treatments for Neurological Disorders and Cancer)
Current Pharmaceutical Design Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles
Current Medicinal Chemistry Ligand Binding Domain of Vitamin D Receptors
Current Topics in Medicinal Chemistry DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry Prediction of Gene Co-Expression by Quantifying Heterogeneous Features
Current Bioinformatics Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Cellular and Physiological Effects of Short-Chain Fatty Acids
Mini-Reviews in Medicinal Chemistry Vascular Homing Peptides with Cell-Penetrating Properties
Current Pharmaceutical Design Nanocellulose-based Delivery Systems and Cervical Cancer: Review of the Literature
Current Pharmaceutical Design HIF Inhibitors: New Hope for Cancer Therapy
Letters in Drug Design & Discovery Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions
Current Molecular Pharmacology Targeting Urokinase and the Transferrin Receptor with Novel, Anti-Mitotic N-Alkylisatin Cytotoxin Conjugates Causes Selective Cancer Cell Death and Reduces Tumor Growth
Current Cancer Drug Targets Role of T Lymphocytes in the Development of Rheumatoid Arthritis. Implications for Treatment
Current Pharmaceutical Design Lapatinib as a Dual Tyrosine Kinase Inhibitor Unexpectedly Activates Akt in MDA-MB-231 Triple-Negative Breast Cancer Cells
Letters in Drug Design & Discovery